Furthermore, the JNK pathway activator (Anisomycin) exhibited the equivalent effect as CSF, while the JNK pathway inhibitor (SP600125) inhibited the antioxidant effect of CSF [68], suggesting that CSF could function as a candidate drug for diabetic ketoacidosis. This evidence concerns the gene MAPK8 and diabetic ketoacidosis.